The FDA has just announced that the 32mg single intravenous dose (IV) of the anti-emetic drug Zofran (ondansetron) will no longer be marketed. This decision came after the June 2012 safety update regarding QT interval prolongation with this dose. The FDA continues to recommend the IV regimen of 0.15mg/kg for prevention of chemotherapy-induced nausea and vomiting however stresses that no single IV dose exceed 16mg. What are some reasons why drugs are withdrawn from the market?
For more information, please read the announcement from the FDA
“Image courtesy of [winnond]/ FreeDigitalPhotos.net“